Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.

about

Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor.

Item

http://www.wikidata.org/entity/Q49206807

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Next-generation sequencing in ...... r a superficial bladder tumor.

@en

Next-generation sequencing in ...... r a superficial bladder tumor.

@nl

type

Item

label

Next-generation sequencing in ...... r a superficial bladder tumor.

@en

Next-generation sequencing in ...... r a superficial bladder tumor.

@nl

prefLabel

Next-generation sequencing in ...... r a superficial bladder tumor.

@en

Next-generation sequencing in ...... r a superficial bladder tumor.

@nl

P1476

Next-generation sequencing in ...... r a superficial bladder tumor.

@en

P2093

Andrew Butterfield

http://www.w3.org/2001/XMLSchema#string

Sumati Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular characterization of urothelial bladder carcinoma

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies

Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association.

Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia.

Recurrence of high-risk bladder cancer: a population-based analysis.

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity.

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansi

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG.

P304

1198-1202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/TAU.2017.11.27

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29354512

http://www.w3.org/2001/XMLSchema#string

P932

5760389

http://www.w3.org/2001/XMLSchema#string